Compare AbbVie Inc (ABBV) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Las Vegas Sands Corp. — how do they compare? AbbVie Inc trades at $248.76 (market cap $441.94B), while Las Vegas Sands Corp. trades at $45.98 (market cap $29.44B). The key difference: AbbVie Inc is far larger — about 15× Las Vegas Sands Corp.'s market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | LVS | |
|---|---|---|
Market Cap | $441.94B | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $69.49 |
52-Week Low | $197.38 | $44.78 |
Enterprise Value | $506.19B | $41.33B |
Dividend Yield | 2.77% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.
Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.
LVS trades at $45.75, up 0.64% over the past 24 hours, with a bearish technical signal but strong fundamentals including a P/E of 17.62 and net income margin of 12.59%. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains robust cash flow from operations at $3.02 billion in 2025 and has announced a $0.30 dividend for H2 2026, reflecting financial stability.
The outlook for LVS is cautiously optimistic, supported by analyst consensus price target of $60.75 and 59% buy ratings. Key opportunities include revenue growth and ESG achievements, while risks involve high debt levels and competitive pressures in the gaming sector. Investors should weigh solid profitability against macroeconomic and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
